Akebia Therapeutics Inc. (AKBA)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akebia Therapeutics Inc. chart...

About the Company

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

CEO

John Butler

Exchange

NASDAQ

Website

https://akebia.com/

$194M

Total Revenue

353

Employees

$368M

Market Capitalization

-5.47

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKBA News

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

4d ago, source:

On Akebia Therapeutics Inc ( NASDAQ:AKBA) released its 8-K filing, detailing the fourth quarter and full-year financial ...

Buy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Position

3d ago, source:

Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

AKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023

on MSN ago, source:

AKBA stock results show that Akebia Therapeutics beat on revenue for the fourth quarter of 2023.More From InvestorPlace The ...

Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)

2d ago, source: Business Insider

and Apogee Therapeutics, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akebia Therapeutics with a $4.33 average price target, representing a 170.6% upside.

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

4d ago, source: Zacks.com on MSN

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

3d ago, source:

Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferri ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

1d ago, source:

It's been a pretty great week for Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders, with its shares surging ...

Earnings Preview For Akebia Therapeutics

5d ago, source:

Akebia Therapeutics AKBA is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement. Analysts estimate that Akebia ...

Recap: Akebia Therapeutics Q4 Earnings

4d ago, source:

Akebia Therapeutics AKBA reported its Q4 earnings results on Thursday, March 14, 2024 at 04:15 PM. Here's what investors need to know about the announcement. Akebia Therapeutics beat estimated ...

Digital medicine maker Akili slashed executive pay in 2023

7d ago, source:

Top executives at therapeutic video game maker Akili got significantly less in total compensation in 2023 compared to the ...

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know

17d ago, source: Zacks.com on MSN

Akero Therapeutics, Inc. (AKRO) closed the last trading session at $26.99, gaining 28.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...